BOLD Longevity Growth Fund

BOLD Longevity Growth is a Boston-based venture capital fund founded in 2023 that invests in late-stage longevity biotech and AI firms addressing the root causes of aging and age-related diseases. The fund specializes in growth-stage investments at the intersection of longevity science, biotechnology innovation, and artificial intelligence. Its portfolio features next-generation therapeutics for oncology/immunology/inflammatory disease (BigHat Biosciences), AI-driven drug discovery for neurodegeneration/autoimmunity/aging (Verge Genomics), precision diagnostics using cfDNA for cancer/autoimmune therapy selection (Aqtual), surgical navigation with AI-powered imaging platforms (Proprio), among others. The team has a strong track record with prior investments in gene editing technologies more efficient than CRISPR and advanced diagnostic wearables[2][6].